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Abstract
Previously, we demonstrated that reproductive senescence in female triple transgenic Alzheimer’s (36TgAD) mice was
paralleled by a shift towards a ketogenic profile with a concomitant decline in mitochondrial activity in brain, suggesting a
potential association between ovarian hormone loss and alteration in the bioenergetic profile of the brain. In the present
study, we investigated the impact of ovariectomy and 17b-estradiol replacement on brain energy substrate availability and
metabolism in a mouse model of familial Alzheimer’s (36TgAD). Results of these analyses indicated that ovarian hormones
deprivation by ovariectomy (OVX) induced a significant decrease in brain glucose uptake indicated by decline in 2-
[18F]fluoro-2-deoxy-D-glucose uptake measured by microPET-imaging. Mechanistically, OVX induced a significant decline in
blood-brain-barrier specific glucose transporter expression, hexokinase expression and activity. The decline in glucose
availability was accompanied by a significant rise in glial LDH5 expression and LDH5/LDH1 ratio indicative of lactate
generation and utilization. In parallel, a significant rise in ketone body concentration in serum occurred which was coupled
to an increase in neuronal MCT2 expression and 3-oxoacid-CoA transferase (SCOT) required for conversion of ketone bodies
to acetyl-CoA. In addition, OVX-induced decline in glucose metabolism was paralleled by a significant increase in Ab
oligomer levels. 17b-estradiol preserved brain glucose-driven metabolic capacity and partially prevented the OVX-induced
shift in bioenergetic substrate as evidenced by glucose uptake, glucose transporter expression and gene expression
associated with aerobic glycolysis. 17b-estradiol also partially prevented the OVX-induced increase in Ab oligomer levels.
Collectively, these data indicate that ovarian hormone loss in a preclinical model of Alzheimer’s was paralleled by a shift
towards the metabolic pathway required for metabolism of alternative fuels in brain with a concomitant decline in brain
glucose transport and metabolism. These findings also indicate that estrogen plays a critical role in sustaining brain
bioenergetic capacity through preservation of glucose metabolism.
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Introduction
Previously we demonstrated that a decline in mitochondrial
bioenergetics precedes the development of AD pathology in the
female triple transgenic Alzheimer’s (36TgAD) mouse model [1].
In both normal and 36TgAD mice, reproductive senescence, both
natural and ovariectomy-induced, resulted in a significant decline
in aerobic glycolysis, PDH, and Complex IV cytochrome c oxidase
activity, and mitochondrial respiration. Following transition
through reproductive senescence, enzymes required for long-chain
fatty acid (HADHA) and ketone body (SCOT) metabolism were
significantly increased whereas cytochrome c oxidase (Complex
IV) collapsed by 40% in both the nonTg and 36TgAD brain
which was predictive of a concomitant decline in ATP generation.
These bioenergetic changes, observed during natural reproductive
senescence, were recapitulated in an ovariectomy model of
menopause [2].
Consistent with findings from basic science discoveries, data
emerging from clinical positron emission tomography with 2-
[18F]fluoro-2-deoxy-D-glucose (FDG-PET) analyses indicate a
progressive reduction in cerebral glucose metabolic rate
(CMRglu), particularly in posterior cingulate (PCC) and parietal-
temporal cortex, in persons with Alzheimer’s disease as well as
those at increased risk for AD [3–7]. Clinical imaging has also
indicated a spatial correlation between increased aerobic glycolysis
and b-amyloid deposition in the ‘‘default mode network’’ brain
areas, suggesting that deficits in energy supply may underlie the
vulnerability to the AD pathogenic process in such areas [8,9].
Further in persons with AD, compromised brain glucose
metabolism is accompanied by parallel activation of alternative
metabolic pathways, as evidenced by a utilization ratio of 2:1
glucose to alternative substrate in persons with incipient AD
compared to a ratio of 29:1 in healthy elderly controls [10].
Earlier studies indicated that 17b-estradiol (E2) promoted
glucose uptake [11], glycolysis [12], glycolytic-coupled tricarbox-
ylic acid cycle (TCA) function, mitochondrial respiration and ATP
generation [2,13–15]. Results of these discovery analyses demon-
strate that 17b-estradiol sustains the ability of the brain to
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transport and utilize glucose as its primary fuel source. From a
translational perspective, these basic science findings are supported
by clinical analyses of glucose metabolism in menopausal women.
Postmenopausal women on estrogen therapy were reported to
have increased cerebral blood flow and cerebral metabolism
relative to non-users [2,16–18]. Further, non-users exhibited a
significant decline in glucose metabolic rate, particularly in the
posterior cingulate and prefrontal cortex, which closely resembled
the hypometabolic profile of AD brains [17,18]. Collectively, both
preclinical analyses in animal models [1,2,19] and clinical
observations [5–7,17] provide compelling evidence in support of
decline in bioenergetic function in brain as an early indicator of
neurodegenerative risk.
In the present study, we sought to investigate the impact of loss
of ovarian hormones and the efficacy of 17b-estradiol to sustain
aerobic glycolysis as a primary bioenergetic system of the brain.
Specifically, we determined whether these bioenergetic deficits
were in response to a decline in substrate availability as evidenced
by capacity for glucose uptake, substrate (glucose, lactate/ketone
body) transporter expression and/or enzyme systems required for
glucose metabolism. The goal of these analyses was to determine
the initiating events that lead to a dysfunctional bioenergetic
system in brain. As a translational preclinical model relevant to
reproductive aging in the human, we utilized temperature and
body weight dysregulation in the ovariectomized 36TgAD mouse
model as the trigger to initiate analyses of brain metabolism.
Results presented herein demonstrate that in 36TgAD mice,
ovarian hormone loss caused by OVX induces a decline in brain
glucose uptake, which could be partially attributed to decreased
glucose transporter expression and compromised hexokinase
activity. The OVX induced decline in cerebral glucose metabolism
was accompanied by the activation of alternative metabolic
pathways. Further, E2 treatment initiated at the time of OVX
prevented the bioenergetic fuel shift by sustaining key elements in
glucose metabolism in brain.
Materials and Methods
Animal Treatments and Ethics
All rodent experiments were performed following National
Institutes of Health guidelines on use of laboratory animals and an
approved protocol (protocol number: 10217) by the University of
Southern California Institutional Animal Care and Use Commit-
tee. The presented study has been approved by the University of
Southern California Institutional Animal Care and Use Commit-
tee (Ethics Committee).
Transgenic mice
Colonies of the 36TgAD mice strain (129S; Gift from Dr.
Frank Laferla, University of California, Irvine) [20] were bred and
maintained at the University of Southern California (Los Angeles,
CA) following National Institutes of Health guidelines on use of
laboratory animals and an approved protocol by the University of
Southern California Institutional Animal Care and Use Commit-
tee. Mice were housed on 12 hours light/dark cycles and provided
ad libitum access to food and water. The characterization of
amyloid and tau pathologies, as well as synaptic dysfunction in this
line of mice has been described previously [20] and confirmed in
our laboratory. Mice were genotyped routinely to confirm the
purity of the colony. To ensure the stability of AD-like phenotype
in the 36TgAD mouse colony, we performed routine immuno-
histochemical assays every 3 to 4 generations. Only offspring from
breeders that exhibit stable AD pathology were randomized into
the study.
Experimental design
To investigate the change in substrate availability following
removal of ovaries and treatment with 17b-estradiol(E2), 6-month-
old 36TgAD mice were randomly assigned into the following
three treatment groups (n = 7 per group): sham ovariectomized
(Sham-OVX), ovariectomized (OVX), and OVX plus 17b-
estradiol (OVX+E2). Mice were bilaterally OVX and injected
with corn oil or coin oil containing E2 (50 mg/kg, Subcutaneously)
daily for 5 weeks (Fig.1).
Body weight and tail skin temperature (TST)
measurement
Body weight and tail skin temperature (TST) were monitored
twice per week during the sleep cycle. To allow mice recover from
the OVX surgery, measurements started one week after the
surgery. TST measurements were conducted using an infrared
thermometer (BIO-152-IRB, Bioseb, Chaville, France) designed
for small rodents. TST was measured twice per week until an
increase of 1 degree or higher of temperature was detected and
sustained for 1 week. Body weight was also determined twice per
week subsequent to skin tail temperature measurement. Following
one week of sustained temperature dysregulation, mice underwent
FDG-PET imaging.
FDG-microPET and microCT imaging
Mice were maintained under anesthesia during microPET and
microCT scans with 2-2.5% isoflurane in oxygen. Scans were
performed in an imaging chamber equipped with a nose cone for
anesthesia delivery and heating pad for body temperature control.
MicroPET imaging was performed with a microPET R4 rodent
model scanner (Concorde Microsystems Inc, Knoxville, TN) and
micro CT imaging was performed on MicroCAT II tomography
(Siemens Preclinical Solutions, Knoxville, TN). Mice were injected
intravenously via the tail vein with radiotracer [18F] Fluoro-2-
deoxy-2-D- glucose (FDG, 200 mCi, 100 uL). Radioactive dose
Figure 1. Experimental paradigm. 6-month-old 36TgAD mice were
randomly assigned into the following three treatment groups (n = 7 per
group): sham ovariectomized (Sham-OVX), ovariectomized (OVX), and
OVX plus 17b-estradiol (OVX+E2). Mice were bilaterally OVX and
injected with corn oil or corn oil with E2 (50 mg/kg, Subcutaneously)
daily for 5 weeks. Weight and tail skin temperature were monitored
twice per week during the sleep cycle before FDG-microPET imaging.
After FDG-microPET imaging, mice were sacrificed for in vitro analyses
of substrate transport and utilization.
doi:10.1371/journal.pone.0059825.g001
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was determined prior to injection by radioisotope dose calibrator
(Capintec, CRC-712M). At 40 min post-injection of FDG, each
mouse was positioned in the microPET scanner in the center of
the 10.8 cm transaxial and 8 cm axial field of view (FOV). Brain
microPET data were collected for 10 min followed by a 10 min
microCT scan for the purpose of co-registration.
Co-registration of microPET and microCT data was performed
using the AMIDE software package (http://amide.sourceforge.
net/). After co-registration of the PET and CT images, ROI
(region of interest) was defined and used to measure the
radioactivity concentration in brains. Decay correction was used
to adjust the actual radioactivity dosage injected (Actual




, T = T minutes between injected time point and initial time point).
Data were analyzed using Student’s t-test with differences between
groups with a p value,0.05 considered statistically significant.
Brain tissue preparation and Western blot analysis
Upon completion of FDG-microPET imaging, 36TgAD mice
(n = 7 per group) were sacrificed and the brains rapidly dissected
on ice. Hippocampus was processed for protein extraction using
Tissue Protein Extraction Reagent (Thermo Scientific, Rockford,
IL, USA) with phosphatase and protease inhibitors (Sigma, St.
Louis, MO, USA), and protein concentrations were determined
with the Bio-Rad Bradford assay. Equal amounts of protein
(20 mg/well) were loaded in each well of a 12.5% SDS PAGE
criterion gel (Bio-Rad, Hercules, CA) and electrophoresed with
Tris/glycine running buffer. Proteins were transferred to 0.45 mm
pore size polyvinylidene difluoride (PVDF) membranes and
immuneblotted with GLUT1 (glucose transporter 1) antibody
(1:1500, Abcam, Cambridge, MA, USA), GLUT3 (glucose
transporter 3) antibody (1:1000, Abcam, Cambridge, MA, USA),
Hexokinase II antibody (1:1000, Millipore, Billerica, MD, USA),
MCT2 (Monocarboxylate transporter 2) antibody (1:1000, Milli-
pore, Billerica, MD, USA), SCOT (3-oxoacid-CoA transferase)
antibody (1:100, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), LDHB (lactate dehydrogenase B) antibody (1:1000, Abcam,
Cambridge, MA, USA), and LDH V (lactate dehydrogenase V)
antibody (1:1000, Abcam, Cambridge, MA, USA). HRP-conju-
gated anti-rabbit antibody and HRP-conjugated anti-mouse
antibody (Vector Laboratories, Burlingame, CA, USA) were used
as secondary antibodies. Immunoreactive bands were visualized
with Pierce SuperSignal Chemiluminescent Substrates (Thermo
Scientific, Waltham, MA, USA) and captured by Molecular
Imager ChemiDoc XRS System (Bio-Rad Laboratories, Hercules,
CA, USA). All band intensities were quantified using the Un-Scan-
it (version 6.0, Silk Scientific, Orem, UT, USA) software.
Hexokinase activity assay
Hexokinase activity assay was measured by monitoring the
conversion of NAD+ (nicotinamide adenine dinucleotide) to
NADH (reduced nicotinamide adenine dinucleotide) by following
the change in absorption at 340 nm. The assay medium
contained: 0.1 mg/mL of the hippocampal tissue protein, 0.05 M
Tris*HCl, PH 8.0, 13.3 mM MgCl2, 0.112 M glucose, 0.227 mM
NAD+, 0.5 mM Adenosine 59Triphosphate, and 1I U/mL
glucose-6-phosphate dehydrogenase (Leuconostoc mesenteroides) in a
final volume of 150 mL. The OD at l= 340 nm was measured
every 1 min for 30 mins at a temperature of 30uC. The increase in
OD reflects the increase in NADPH concentration, and the total
hexokinase activity was calculated from the slope of the resulting
curve.
Serum b-hydroxybutyrate measurement
The concentration of serum b-hydroxybutyrate was determined
by b-hydroxybutyrate liquicolor assay kit (Stanbio laboratory, TX,
USA) following manufacturer’s instructions.
Real-time RT-PCR gene expression profiling
Total RNA was isolated from mouse hippocampal tissues using
the RNeasy kit (Qiagen, Valencia, CA). The quality and quantity
of RNA samples were determined using the Experion RNA
analysis kit (Bio-Rad, Hercules, CA). RNA samples were reverse-
transcribed to cDNA using the high capacity cDNA reverse
transcription kit (Applied Biosystems, Foster City, CA) and stored
at 280uC for gene expression analysis. Taqman low-density arrays
(TLDA) were custom manufactured at Applied Biosystems. Real-
time RT-PCR experiment and data analysis were conducted
following the methods as described in our previous report [21].
Results
Ovariectomy induced increase in body weight and tail
skin temperature (TST): prevention by 17b-estradiol
It is well documented that ovarian hormone loss is associated
with increased body weight and temperature dysregulation in
menopausal women [22]. In this study, we used OVX mice as a
translational model of surgically oophorectomized premenopausal
women. In this model, body weight and tail skin temperature
served as surrogate markers of metabolic and temperature
dysregulation [23]
OVX rapidly induced a significant increase in body weight
(Fig. 2A; 2.9460.39 (OVX group) vs. 0.2760.54 (Sham-OVX
group), F (2, 13) = 12.61, p,0.001, n = 5–6) one week after surgery
and this increase was sustained throughout the duration of the
experiment. E2 treatment initiated at the time of OVX prevented
OVX-induced body weight increase. OVX also induced a
significant rise in tail skin temperature 4 weeks after the OVX
surgery, which reached asymptote by week 5. Asymptotic
temperature triggered in vivo brain glucose imaging followed by
in vitro analyses (Fig.1). Tail skin temperature of OVX animals
increased 1 uC60.03 uC (Fig. 2B; 23.2460.08 (OVX group) vs.
22.2860.07 (Sham-OVX group), F (2,13) = 42.21, p,0.001,
n = 5–6) by week 5 relative to Sham-OVX animals. OVX-induced
rise in tail skin temperature was prevented by E2 treatment
initiated at the time of OVX.
Ovariectomy induced decrease in brain glucose uptake:
partial prevention by 17b-estradiol
Ovarian hormone loss is associated with cerebral metabolic
decline [16,17]. In the current study, we sought to determine
whether loss of ovarian hormones and associated decline in brain
metabolism were accompanied by a change in brain glucose
uptake. To address this question, FDG-microPET imaging was
conducted to determine the impact of ovarian hormone loss and
E2 treatment (50 mg/kg, daily SC) on brain glucose uptake in 6-
month 36TgAD female mice. Compared to the Sham-OVX
group, 5 weeks OVX induced a significant 25% decline in brain
glucose uptake (Fig. 3A; 74.161.9% (OVX group) vs. 10065.4%
(Sham-OVX group), p,0.05, n = 7). Decline in brain glucose
uptake was coincident with thermal dysregulation in the OVX
condition (Fig. 2B). E2 treatment (50 mg/kg, daily SC) at the time
of OVX partially prevented the OVX-induced decline in brain
OVX Induce Metabolic Fuel Shift in Female AD Brain
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glucose uptake (Fig. 3A; 84.262.9% (E2 group) vs. 74.161.9%
(OVX group), p,0.05, n = 4–7), consistent with the prevention of
thermal dysregulation and weight gain (Fig. 2).
Ovariectomy induced decrease in brain glucose
transporter expression: prevention by 17b-estradiol
The OVX-induced decrease in brain glucose uptake could be
attributed to multiple levels of metabolic dysregulation, including
reduced glucose transport, compromised glycolysis, deficient
mitochondrial capacity and impaired ATP generation [2,13–15].
In these experiments, we determined the impact of ovarian
hormone deprivation and E2 on the expression of glucose
transporters in brain and neural cells via specific glucose
transporters (GLUT) expressed in blood brain barrier (BBB)
endothelial cells (GLUT1, 55 KDa), glial cells (GLUT1, 45 KDa)
and neurons (GLUT3) [24].
To investigate whether the OVX-induced decline in brain
glucose uptake is correlated with compromised glucose transport,
expression of BBB GLUT155 Kda, glial GLUT145 Kda and
neuronal GLUT3 was assessed. BBB GLUT155 Kda expression
was significantly decreased 38% by OVX (Fig 3B; 62.16613.59%
(OVX group) vs. 10068.37% (Sham-OVX group), p,0.05,
n = 5–6) in 36TgAD female mice. Treatment with E2 completely
prevented the OVX-induced decline in BBB GLUT155 Kda
expression (Fig 3B; 96.4265.56% (E2 group) vs. 62.16613.59%
(OVX group), p,0.05, n = 5–6). However, the expression level of
GLUT155 Kda did not correlate with complete reversal of brain
glucose uptake relative to Sham-OVX (Fig. 3A). This finding
indicated that other key enzymes involved in brain glucose
metabolism are required for complete reversal of the OVX-
induced decline in glucose uptake.
OVX also induced a 20% decline (Fig 3C; 80.63610.68%
(OVX group) vs. 100610.28% (Sham-OVX), p.0.1, n = 5–6) in
neuronal GLUT3 expression, which was partially prevented by E2
(Fig 3C; 88.1168.05% (E2 group) vs. 80.63610.68% (OVX
group), p.0.1, n = 5–6). Neither OVX nor E2 had a significant
effect on the glial transporter GLUT145 Kda protein expression
(Fig 3D). Collectively, these data indicate that ovarian hormone
loss compromised glucose transport through the blood brain
barrier (BBB) and neurons and spared glial glucose transporter
expression. E2 prevented the OVX-induced decline of BBB
GLUT155 Kda expression, with a partial preventative effect on
neuronal GLUT3 expression. Further, the glial glucose transporter
is not regulated by ovarian hormones as evidenced by no change
in response to OVX and E2.
Ovariectomy induced decrease in hexokinase expression
and activity: prevention by 17b-estradiol
In neurons and glial cells, glucose is irreversibly phosphorylated
to glucose-6-phosphate by hexokinase, which is the first and rate-
limiting step in glycolysis. The glucose uptake signal in FDG-PET
imaging is also dependent upon hexokinase activity, as cellular
FDG accumulation is mediated by hexokinase that phosphorylates
FDG to FDG-6-phosphate, which does not undergo further
metabolism [25]. To investigate whether OVX-induced decline in
glucose uptake is associated with compromised glucose phosphor-
ylation, we first analyzed the expression of hexokinase type II,
which is the isozyme sensitive to hormonal regulation [26]. In
36TgAD female brain, OVX induced a significant 30% decline in
hexokinase II protein expression (Fig 4A; 68.4968.01% (OVX
group) vs. 10068.03% (Sham-OVX group), p,0.05, n = 5–6),
which was partially but not significantly prevented by E2 (Fig 4A;
86.17610.61% (E2 group) vs. 68.4968.01% (OVX group),
p = 0.11, n = 5–6). The OVX-induced decline in hexokinase
expression was paralleled by a significant decline in hexokinase
activity, although this 15% decline was not as great as the decline
in protein expression (Fig 4B; 84.8065.26% (OVX group) vs.
10063.4% (Sham-OVX group), p,0.05, n = 5–6). As with
protein expression, E2 partially but not significantly prevented
the OVX-induced decline in hexokinase activity (Fig 4B;
96.0767.43% (E2 group) vs. 84.8065.26% (OVX group),
p = 0.14, n = 5–6).
The magnitude of the OVX-induced decline in hexokinase
protein expression and activity was positively correlated with the
OVX-induced decline in brain glucose uptake (Fig. 3A). These
data are consistent with the key role of hexokinase in the FDG-
PET signal [27]. Further, the impact of E2 on preventing decline
in HEX protein expression and activity is consistent its partial
prevention of the OVX-induced decline in FDG-PET signal.
Figure 2. Ovariectomy (OVX) induced increase in body weight
and tail skin temperature and prevention by 17b-estradiol. A.
OVX induced a significant increase in body weight (0.2760.54 vs.
2.9460.39, F (2, 13) = 12.61, p,0.001, n = 5–6) one week after surgery,
which was sustained through the duration of the experiment. E2
treatment (50 mg/kg, SC) initiated at time of OVX prevented the OVX-
induced body weight gain. B. OVX induced a significant rise
(22.2860.07 vs. 23.2460.08, F (2,13) = 42.21, p,0.001, n = 5–6) in tail
skin temperature 4 weeks after surgery, and E2 treatment (50 mg/kg, SC)
initiated at time of OVX prevented the OVX-induced increase in tail skin
temperature.
doi:10.1371/journal.pone.0059825.g002
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Ovariectomy induced a shift in LDH1 and LDH5 ratio:
prevention by 17b-estradiol
Decreased glucose supply and utilization could activate
alternative metabolic pathways to compensate for decline in brain
glucose metabolism. As we and others have shown, neurons can
utilize lactate or ketone bodies as alternative fuels [19,28–30]. In
response to energetic demand, brain can utilize lactate to sustain
synaptic transmission, whereas under prolonged glucose depriva-
tion, the brain will utilize ketone bodies generated from the liver to
support the energetic demand [31]. To investigate whether OVX
induced a shift in utilization of alternative fuels, we first
determined lactate dehydrogenase protein expression level in the
Sham-OVX, OVX and OVX+E2 mice. Multiple isoforms of
lactate dehydrogenase are expressed in glial and neuronal cell
types, which enable these cells to generate and utilize lactate. The
LDH5 isoform, which is composed of four A subunits, converts
pyruvate to lactate in glial cells. LDH1 isoform, which is formed
by four B subunits, converts lactate to pyruvate for ATP
generation in neurons [32,33]. In the OVX condition, LDH5
glial cell expression was dramatically increased (Fig 5A;
178633.34% (OVX group) vs. 100614.51% (Sham-OVX group),
p,0.05, n = 5–6). In neurons, LDH1 expression exhibited a
similar increase in expression, although not significant (Fig 5B;
125.22616.32% (OVX group) vs. 10068.69% (Sham-OVX
group), p = 0.09, n = 5–6).
An increased LDH5/LDH1 ratio can be indicative of elevated
lactate in the mouse and human brain, and is consistent with an
aging phenotype [34,35]. Based on the elevated expression of
LDH5 to LDH1, we tested whether there was a significant
increase in LDH5 to LDH1 ratio. The ratio of LDH5/LDH1
expression was significantly increased in the OVX condition
relative to Sham-OVX (Fig 5C; 139.7069.37% (OVX group)
vs.100610.72% (Sham-OVX group), p,0.05, n = 5–6). Animals
treated with E2 at the time of OVX did not exhibit an increase in
the LDH5/LDH1 ratio and were indistinguishable from Sham-
OVX (Fig 5C; 76.36610.90% (E2 group) vs.100610.72% (Sham-
OVX group), p = 0.16, n = 5–6). Under OVX condition, the
increased expression of the enzyme LDH5 required for conversion
of pyruvate to lactate by glial cells is predicative of greater lactate
generation relative to consumption in neurons, suggesting the
potential of lactate accumulation in the hippocampus. Prevention
of the rise in LDH5 expression and prevention of the increase in
LDH5/LDH1 ratio by E2 is predicative of balanced lactate
generation to utilization in hippocampus.
Ovariectomy activated the ketogenic pathway:
prevention by 17b-estradiol
Under prolonged glucose deprivation, the brain can utilize
ketone bodies as energy substrates. To determine whether OVX
induced a shift in utilization to ketone bodies, we determined
ketone body level and the expression of the ketone body
transporter MCT2 and the metabolic enzyme Succinyl-CoA: 3-
ketoacid CoA transferase (SCOT) required to convert ketone
bodies to acetyl-CoA. To assess liver generation of ketone bodies
as an alternative fuel for utilization by brain, we determined the
level of b-hydroxybutyrate in the plasma [36]. OVX induced a
significant 150% rise in the serum level of b-hydroxybutyrate
(Fig 6A; 0.288660.0897 (OVX group) vs. 0.114260.0132 (Sham-
OVX group), p,0.05, n = 5–6), the major circulating ketone body
generated by the liver. In parallel with the increased ketone levels,
Figure 3. Ovariectomy (OVX) induced decline in brain glucose uptake and BBB GLUT155 Kda expression: prevention by 17b-
estradiol. A. Representative FDG-microPET images showed a decline in brain glucose uptake in OVX condition, which was partially prevented by E2
treatment (50 mg/kg, SC). (Red and yellow indicate higher values; green and blue indicate lower values). B. Quantitative analysis of brain glucose
uptake demonstrated a significant decrease in OVX condition (**, p,0.01, bars represent mean value6SEM, n = 5–7), which was partially prevented
by E2 treatment (50 mg/kg, SC) (*, p,0.05; bars represent mean value6SEM, n = 5–6). C. OVX induced a significant decrease in protein expression of
blood brain barrier glucose transporter 1 (GLUT155 Kda), which was prevented by E2 treatment (50 mg/kg, SC). (*, p,0.05, bars represent mean value
6 SEM, n = 5–6). D. OVX induced a 20% decrease in protein expression of neuronal glucose transporter (GLUT3), which is partially prevented by E2
treatment (50 mg/kg, SC). E. No change in expressions of glial glucose transporter (GLUT145 Kda) between Sham-OVX, OVX and OVX+E2 groups.
doi:10.1371/journal.pone.0059825.g003
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protein expression of neuronal monocarboxylate transporter
(MCT2), which transports ketone bodies or lactate, was increased
by 50% in the OVX condition (Fig 6B; 153.3467.63% (OVX
group) vs. 10064.41% (Sham-OVX group), p,0.05, n = 5–6).
SCOT, the key enzyme that catabolizes ketone bodies to acetyl-
CoA for subsequent ATP generation, was also increased by OVX
(Fig 6C; 130.40611.60% (OVX group) vs. 100610.60% (Sham-
OVX group), p = 0.09, n = 5–6). Treatment with E2 initiated at
the time of OVX prevented OVX-induced increase in b-
hydroxybutyrate level (Fig 6A; 0.130460.0232 (E2 group) vs.
0.288660.0897 (OVX group), p = 0.06, n = 5–6) and expression of
MCT2 (Fig 6B; 126.4269.48% (E2 group) vs. 153.3467.63%
(OVX group), p = 0.06, n = 5). E2 treatment also significantly
prevented the protein expression of SCOT (Fig 6C; 95.8465.54%
(E2 group) vs. 125.14614.25% (OVX group), p,0.05, n = 5–6).
Collectively, the data indicate that OVX induces a significant rise
in the generation of ketone bodies, the enzyme required to convert
ketone bodies to acetyl-CoA and transport of ketone bodies into
neurons. E2 treatment at the time of OVX prevented the rise in
the ketogenic system.
Ovariectomy induced increase in b-amyloid levels in
brain: prevention by 17b-estradiol
Previous analyses demonstrated that female 36TgAD mouse
model showed an age-related increase in b-amyloid deposition in
brain [1]. To investigate whether an increase in b-amyloid level is
associated with ovarian hormone loss, we assessed the b-amyloid
oligomers in the 36TgAD cortex samples. We characterized three
major Ab related bands: full length APP band (,100 Kda), Ab
Figure 4. Ovariectomy (OVX) induced decrease in hexokinase
expression and activity: prevention by 17b-estradiol. A. In
female 36TgAD brains, OVX induced a significant decrease in protein
expression of hexokinase 2 (*, P,0.05, bars represent mean value6SEM,
n = 526), which was partially prevented by E2 treatment. B. OVX
induced a significant decrease in hexokinase activity (*, p,0.05, bars
represent mean value 6 SEM, n = 5–6), which was partially prevented
by E2 treatment.
doi:10.1371/journal.pone.0059825.g004
Figure 5. Ovariectomy (OVX) induced a shift in LDH1 and LDH5
ratio and prevention by 17b-estradiol. A. OVX induced a significant
increase (*, p,0.05, bars represent mean value 6 SEM, n = 5–6) in the
expression of glial lactate dehydrogenase 5 (LDH5) expression. B. OVX
induced a 25% increase in neuronal lactate dehydrogenase 1 (LDH1). C.
The lactate production indicator, LDH5/LDH1 ratio increased signifi-
cantly (*, p,0.05, bars represent mean value 6 SEM, n = 5–6). All OVX-
induced changes were prevented by E2 treatment.
doi:10.1371/journal.pone.0059825.g005
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dodecamers (56 Kda) and Ab hexamers (27 Kda) (Fig. 7A). There
was no significant difference in APP expression across all three
groups (Fig. 7B). Compared to the Sham OVX, OVX induced a
significant increase in the protein level of Ab oligomers (Fig. 7C
and 7D; 56 Kda Ab: 241632.3% (OVX group) vs. 100613.3%
(Sham-OVX group), p,0.01; 27 Kda Ab: 19768.7% (OVX
group) vs. 10068.7% (Sham-OVX group), p,0.01; n = 4–6). E2
treatment partially prevented the OVX-induced increase in Ab
oligomer levels (Fig. 7C and 7D; 56 Kda Ab: 180633.7% (E2
group) vs. 241632.3% (OVX group), p = 0.11; 27 Kda Ab:
120632.3% (E2 group) vs. 10068.7% (OVX group), p,0.05;
n = 4–5). Data of analyses suggest that changes in ovarian
hormone status, such as OVX and E2 treatment, induced
alteration in the amyloidogenic pathway and/or Ab clearance
pathway, rather than directly regulating APP availability.
17b-estradiol upregulated bioenergetic gene expression:
a broader impact on brain energy production
To investigate at a systems level the impact of ovarian hormone
loss and E2 treatment on the bioenergetic profile in 36TgAD
mouse brains, we designed a custom bioenergetic low-density gene
array and conducted real time RT-PCR analyses to assess the
expression of key genes involved in brain bioenergetics (Fig. 8A).
Gene expression data presented in the volcano plot displays fold
change vs. p-value (Fig. 8B and Fig. 8C), with significantly
changed genes listed respectively (Fig. 8D and Fig. 8E). Results
presented in the volcano plot demonstrated that when compared
to Sham-OVX, OVX had a relatively small impact with 4 genes
(Sdhc, Idh1, Cpt1c, Star) that exhibited significant changes (Fig. 8B
and Fig. 8D). E2 treatment induced a much broader response with
a total of 10 genes significantly changed when compared to the
OVX group, including 1 gene involved in glycolysis (Pdhb), 4
genes involved in TCA and electron transport chain (ETC) (Sdha,
Sdhb, Uqcrc2, Cyb5b), 3 genes involved in fatty acid metabolism
(Acaa2, Acat1, Hadha), and 2 genes involved in cellular redox and
insulin signaling (Prdx3 and Irs4 respectively) (Fig. 8C and Fig. 8E).
Discussion
In this study, we demonstrated that loss of ovarian hormones
induced a decline in glucose-driven brain bioenergetics, which was
associated with dysregulated body weight and temperature
control. We further identified a compensatory shift from glucose-
driven brain bioenergetics towards an alternative substrate
pathway (lactate and ketone bodies) induced by ovarian hormone
loss. Although E2 treatment completely prevented the dysregula-
tion of body weight and temperature control, the efficacy of E2 to
prevent decline in on bioenergetic capacity of the brain was partial
(Fig. 9).
Classic indicators of ovarian hormone loss occurred in the
ovariectomized 36TgAD mice, evidenced by an increase in body
weight and tail skin temperature within 5 weeks, a time frame
comparable to 2.5 years of human life [37,38]. These results are
consistent with clinical observations of the metabolic and thermal
dysregulation in surgically oophorectomized premenopausal
women [39,40].
It is well known that the decline in brain glucose metabolism is
associated with decreased cognitive function in mild cognitive
impairment and Alzheimer’s disease [3–7,41–43] and, at least,
partially contributes to the neurodegenerative process [31]. ApoE
e4 carriers, who are cognitively normal but at increased risk for
AD, exhibited deficits in cerebral metabolic rate for glucose
(CMRglu) in posterior cingulate (PCC) and parietal temporal
cortex several decades prior to onset of dementia [7]. Further,
cognitively normal people with a maternal family history AD, who
have a higher risk for AD [44], exhibited glucose hypometabolism
in brain regions identified in prodromal AD [41,45]. Collectively,
these data indicate that hypometabolism in brain is an early and
Figure 6. Ovariectomy (OVX) induced activation of ketogenic
pathway and prevention by 17b-estradiol. A. OVX induced a
significant increase (*, p,0.05, bars represent mean value6SEM, n = 5–
6) in serum b-hydroxybutyrate level, which was prevented by E2
treatment. B. OVX induced a significant increase (*, p,0.05, bars
represent mean value 6 SEM, n = 5–6) in the expression of neuronal
monocarboxylate transporter 2 (MCT2), which was prevented by E2
treatment. C. OVX induced a significant increase (*, p,0.05, bars
represent mean value 6 SEM, n = 5–6) in the expressions of 3-oxoacid-
CoA transferase (SCOT), which was prevented by E2 treatment.
doi:10.1371/journal.pone.0059825.g006
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persistent indicator of both risk for and severity of Alzheimer’s
disease [3–7,41].
Results of our analyses to determine the impact of OVX on
expression of glucose transporters in blood brain barrier, neurons
and glial cells indicated a significant reduction in blood brain
barrier specific glucose transporters. The 55 Kda form of GLUT1
mediates glucose transport across the blood brain barrier (BBB)
and is a rate-limiting step for brain glucose utilization under
metabolic demand [46,47]. Findings from the current study in a
mouse model of familial AD are consistent with a decline in BBB
GLUT155 Kda expression in late stage AD and compromised BBB
glucose transport [48]. In patients with GLUT1 deficiency
syndrome, GLUT1 haplo-insufficiency leads to a global decrease
in cortical glucose uptake and multiple neurological deficits
[49,50]. In addition to GLUT1, GLUT3 is also associated with
the pathogenesis of Alzheimer’s [51]. In the current report, 5-week
OVX induced a significant (38%) decrease in the BBB
GLUT155 Kda protein, whereas E2 treatment initiated at the time
of OVX prevented the OVX-induced decline. In contrast to the
BBB GLUT155 Kda, the neuronal glucose transporter GLUT3 and
the glial glucose transporter GLUT145 Kda were not significantly
affected by 5-week OVX or E2 treatment. The decline in BBB
GLUT155 Kda in the face of sustained glial and neuronal GLUT
expression is indicative of compromised BBB glucose transport as
an early response to ovarian hormone loss. These results indicate a
key role of BBB GLUT155 Kda in mediating the decline in the
FDG-PET detected brain glucose uptake induced by ovarian
hormone loss.
In addition to glucose transporters, cerebral glucose utilization is
under tight control by hexokinase, which serves as the first rate-
limiting step in glycolysis. In the current study, ovarian hormone
deprivation induced a significant decline in hexokinase protein
expression as well as activity, which was prevented by E2
treatment in 36TgAD female mice. Hexokinase interaction with
the mitochondrial VDAC also plays an important role in
preventing mitochondria-mediated apoptosis and promoting cell
survival in neurons and other cell types [52–54]. AD patients
exhibit declined hexokinase activity in the brain, cerebral
microvessel, leukocytes and fibroblasts [55–57]. Previous studies
have demonstrated that ovarian hormone loss led to compro-
mised-brain hexokinase activity, whereas short-term estrogen
treatment was efficacious to increase hexokinase activity in rat
brains [12]. Collectively, these data demonstrate that the reduction
in BBB GLUT155 Kda expression and hexokinase activity are key
drivers for the decline in brain glucose uptake.
Lactate is a well described bioenergetic fuel supplied by glia to
neurons and is particularly important under conditions of high
synaptic activity, such as occurs during learning and memory [58].
Further, lactate can serve as an auxiliary fuel during glucose
insufficiency by metabolism of glycogen stores to generate glucose
and subsequently lactate [59]. In the current study, we found that
OVX induced an 80% increase in LDH5, suggestive of increased
production of lactate in glial cells for use as a compensatory
Figure 7. Ovariectomy (OVX) induced increase in b-amyloid level: prevention by 17b-estradiol. A. Three Ab related bands were
characterized: full length APP band (,100 Kda), Ab dodecamers (56 Kda) and Ab hexamers (27 Kda). B. There is no significant change of APP
expressions between Sham-OVX, OVX and OVX+E2 groups. C. OVX induced a significant increase (**, p,0.01, bars represent mean value 6 SEM,
n = 4–6) in the expression of 56 Kda Ab. D. OVX induced a significant increase (**, p,0.01, bars represent mean value 6 SEM, n = 4–6) in the
expression of 27 Kda Ab, which was partially prevented by E2 treatment (*, p,0.05; bars represent mean value6SEM, n = 4–5).
doi:10.1371/journal.pone.0059825.g007
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substrate in neurons. However, LDH1 expression, presumably
neuronal, was modestly although not significantly increased
following OVX. These findings suggest that glial cells are likely
to produce lactate in excess to its utilization by neurons. Increased
LDH5 expression relative to LDH1 is consistent with an
accelerated aging phenotype [34]. This postulate is supported by
data derived from a premature aging model of mitochondrial
mutation with high levels of mtDNA point mutations and linear
deletions. In this model, increased LDH5/LDH1 ratio was
associated with high levels of lactate in brain, which paralleled
that observed in aging [34]. In the current study, the increased
LDH5/LDH1 ratio in the OVX condition suggests that ovarian
hormone loss leads to lactate accumulation and an accelerated-
aging phenotype in the 36TgAD female brain.
Under conditions of prolonged glucose deprivation, the brain
shifts to utilization of ketone bodies as an alternative fuel. Previous
findings from our group demonstrated that the bioenergetic fuel
shift occurred in the 36TgAD brain from the outset and
represents an AD metabolic phenotype [19]. In the current
report, we observed an increase in serum ketone body concentra-
tion, which was accompanied by a simultaneous increase in
hippocampal expression of SCOT, the rate-limiting enzyme for
conversion of ketone bodies to acetyl-CoA for entry into the TCA
cycle. In addition, the neuronal MCT2 transporter for ketone
bodies and lactate was also increased. These changes indicate a
coordinated upregulation of peripheral ketone supply, cellular
transport mechanism and conversion of ketone bodies to
compensate for decline in glucose metabolism in brain. E2
treatment prevented this shift to the ketogenic pathway in brain,
likely via preventing decline of the aerobic glycolytic pathway.
Collectively, these data demonstrated that ovarian hormone loss
induced an accelerated AD phenotype, which was partially
prevented by E2 treatment.
Figure 8. E2 treatment significantly regulated Bioenergetic gene expression. A. Gene list of custom bioenergetic genearray. B. Gene
expression data presented in the valcano plot which displays fold changes vs p-values between Sham-OVX and OVX demonstrated that OVX had little
impact on the expression of the bioenergetic genes. C. Gene expression data presented in the valcano plot which displays fold change vs p-values
between OVX+E2 and OVX demonstrated that E2 treatment exerted a broad impact on the expression of genes involved in bioenergetic pathways.
Each dot representes one individual gene; Red: up-regulated gene expression compared to OVX; Green: down-regulated gene expression compared
to OVX; Dots above the bule line represent genes that are significantly regulated. D. Compared to OVX group, genes that were significantly changed
in Sham-OVX group were categorized into 3 different functional groups: TCA/ETC/Oxphos (tricarboxylic acid cycle/electron transport chain/oxidative
phosphorylation), fatty acid metabolism, and cholesterol trafficking. Data is presented as fold change relative to the OVX group with the
corresponding p value listed for each individual gene. E. Compared to OVX group, genes that were significantly changed in OVX+E2 group were
categorized into 5 different functional groups: glycolysis, TCA/ETC/Oxphos, fatty acid metabolism, redox and IGF signaling. Data is presented as fold
change relative to the OVX group with the corresponding p value listed for each individual gene.
doi:10.1371/journal.pone.0059825.g008
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b-amyloid deposition is the pathological marker of AD and is
proposed to be responsible for cognitive deficits in AD [60–62].
Consistent with the previous findings in hippocampus, the current
study demonstrated that OVX activates amyloidogenic pathway in
cortex, indicating that ovarian hormone loss and E2 treatment
induced a brain-wide systems response in the amyloidogenic
pathway as well as the Ab clearance pathway [2]. In addition,
increased b-amyloid levels paralleled the decline in hexokinase
activity. Previous studies reported that b-amyloid triggers the
release of neuronal hexokinase-1 from mitochondria and inacti-
vates hexokinase-1 [62]. Taken together, these results provide a
plausible mechanism underlying clinical observations that decline
in brain glucose metabolism is associated with an increase in b-
amyloid deposition [30,63].
Gene expression analyses demonstrated that genes involved in
the TCA cycle were increased in the OVX group (Figure 8D),
suggesting a potential compensatory activation of acetyl-CoA
utilization in response to decreased glucose transport and
compromised glycolysis induced by OVX. E2 treatment signifi-
cantly increased the expression of genes in Complex II (Sdha and
Sdhb) and Complex III (Uqcrc2) (Figure 8E), suggesting an up-
regulation in ETC function. Together with the observation that
E2 treatment prevented decline in glucose transporters and
hexokinase activity in cytosolic compartment, these data suggest
a system-level regulation of brain glucose metabolism and
bioenergetic function by E2 in multiple function domains spanning
from glucose transport to glycolysis and to ETC.
In the current study, E2 treatment in the 36TgAD brain
partially prevented OVX-induced decline in whole brain glucose
uptake and a shift to alternative substrates in the hippocampus,
whereas E2 treatment completely prevented dysregulation in
temperature and body weight. The E2 prevention of dysregulation
of temperature and body weight indicates that the E2 dose and
regimen was appropriate to regulate hypothalamic functions. The
dissociation between hypothalamic and hippocampal response to
E2 could be explained by: 1) a different E2 dose requirement; 2)
the 36TgAD female brain has a diminished response to E2; 3) the
necessity for another ovarian hormone, progesterone, as was
shown for prevention of OVX-induced rise in b-amyloid [64].
The purpose of the current study was to determine whether
bioenergetic deficits in mitochondrial function previously observed
[2] were accompanied by changes in glucose availability to sustain
aerobic glycolysis and whether there was activation of compen-
satory responses for the transport and metabolism of alternative
fuels. Collectively, the data demonstrate that loss of ovarian
hormones led to a significant decline of glucose uptake, glucose
transporter expression and in the enzymes required for glucose
metabolism. Coincident with the decline in glucose uptake,
transport and metabolism induced by OVX, there was a
significant rise in the transporter for alternative fuels and the
enzymes required for their metabolism. These results together with
our previous findings demonstrate that loss of ovarian hormones is
associated with a system wide decline in glucose transport and
utilization in brain and a compensatory rise in the systems
required to utilize alternative, less efficient fuels and induced an
accelerated AD phenotype.
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